Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?. Issue 2 (March 2014)

• Record Type: Journal Article
• Authors: Bozza, Claudia; Fontanella, Caterina; Buoro, Vanessa; Mansutti, Mauro; Aprile, Giuseppe
• Is Part Of: Expert review of clinical pharmacology. Volume 8:Issue 2(2015)
• Page Start: 251
• Page End: 265
• Publication Date: 2014-03
• Subjects: Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1586/17512433.2015.1001837
• Languages: English
• ISSNs: 1751-2433

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Since angiogenesis plays an important role in cancer growth, infiltration and metastasis, many agents targeting this pathway have been developed over the last decade. Antiangiogenic drugs interfere with this process and may inhibit neoplastic growth or induce tumor dormancy by blocking the expanding network of newly formed capillaries. Despite the initial promise, targeting angiogenesis in breast cancer has not reached major breakthroughs. Nevertheless, the immunologic role of VEGF deserves to be further explored. We aim to describe the biological mechanisms which underlie the role of angiogenesis in breast cancer carcinogenesis, to depict its contribution to the metastatic process and to review the most important clinical trials testing angiogenic inhibitors in breast cancer, including monoclonal antibodies and novel small molecules.</p> </abstract>